Cidara Therapeutics Current Ratio 2014-2022 | CDTX

Cidara Therapeutics current ratio from 2014 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Cidara Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.06B $0.03B 1.93
2022-06-30 $0.04B $0.03B 1.16
2022-03-31 $0.05B $0.03B 1.62
2021-12-31 $0.07B $0.03B 2.11
2021-09-30 $0.05B $0.03B 1.41
2021-06-30 $0.06B $0.03B 1.80
2021-03-31 $0.05B $0.04B 1.28
2020-12-31 $0.06B $0.04B 1.48
2020-09-30 $0.06B $0.03B 1.78
2020-06-30 $0.07B $0.03B 2.22
2020-03-31 $0.08B $0.03B 2.72
2019-12-31 $0.07B $0.03B 2.18
2019-09-30 $0.08B $0.03B 2.45
2019-06-30 $0.05B $0.02B 2.57
2019-03-31 $0.06B $0.02B 3.19
2018-12-31 $0.08B $0.02B 3.88
2018-09-30 $0.09B $0.01B 6.78
2018-06-30 $0.11B $0.02B 7.11
2018-03-31 $0.07B $0.01B 5.99
2017-12-31 $0.08B $0.01B 6.43
2017-09-30 $0.07B $0.01B 7.68
2017-06-30 $0.08B $0.01B 7.49
2017-03-31 $0.09B $0.01B 13.26
2016-12-31 $0.11B $0.01B 11.83
2016-09-30 $0.08B $0.01B 9.79
2016-06-30 $0.09B $0.01B 17.22
2016-03-31 $0.10B $0.00B 24.04
2015-12-31 $0.11B $0.01B 18.12
2015-09-30 $0.12B $0.00B 26.99
2015-06-30 $0.12B $0.00B 40.11
2015-03-31 $0.06B $0.00B 15.33
2014-12-31 $0.02B $0.00B 7.16
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B $0.00B 1.73
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.087B $0.050B
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00